Every 10-Q that Nuvation Bio Inc (NUVB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NUVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUVB filings page.
Nuvation Bio generated total revenue of $31.7 million for the quarter and $114.9 million for the six months ended June 30, 2026, driven by $41.7 million in net product revenue from IBTROZI and substantial collaboration and license income, including approximately $58.7 million of upfront license revenue from Eisai.
The company reported a six‑month net loss of approximately $57.4 million, improved from the prior‑year period as operating loss narrowed despite higher research and development and selling, general and administrative expenses. Cash, cash equivalents and marketable securities totaled $661.0 million, supported by a $250.0 million 0.75% Convertible Senior Notes offering and a $150 million revenue interest financing tied to U.S. IBTROZI sales. Management expects to continue incurring operating losses but believes existing capital will fund operations for at least 12 months.
Nuvation Bio Inc. reported a sharp turnaround for the quarter ended March 31, 2026, posting net income of $5.4M compared with a loss of $53.2M a year earlier. Total revenue rose to $83.2M from $3.1M, driven by U.S. IBTROZI product sales and a major taletrectinib license deal with Eisai.
Product revenue reached $18.5M, while collaboration and license revenue increased to $64.7M, including about $58.7M of upfront license revenue from Eisai. Operating cash flow improved to a positive $5.1M. The company ended the quarter with $533.7M in cash, cash equivalents and marketable securities and continues to invest heavily in research and development and commercializing IBTROZI.
Nuvation Bio (NUVB) reported Q3 2025 results. Total revenue was $13.1 million versus $0.7 million a year ago, driven by the first commercial sales of IBTROZI in the U.S. Product revenue was $7.7 million, and collaboration and license revenue was $5.4 million. Cost of revenue was $3.3 million, yielding gross profit of $9.8 million.
Operating expenses were $66.2 million (R&D $28.8 million; SG&A $37.4 million). Loss from operations was $56.4 million and net loss was $55.8 million ($0.16 per share). Weighted average shares outstanding were 342.4 million.
Liquidity remained significant with $549.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025. During the nine months, the company received $150.0 million from a revenue interest financing agreement and $48.9 million in borrowings; operating cash outflow was $143.7 million. Total liabilities rose to $275.7 million, including $150.6 million related to the revenue interest financing and $47.1 million in long-term borrowings. IBTROZI began U.S. shipments in June 2025.
Nuvation Bio (NUVB) Q2 2025 10-Q snapshot
- Total revenue rose to $4.83 million (vs. $1.44 million Q2 2024) driven by the first U.S. sales of IBTROZI ($1.24 million) and higher collaboration income.
- Gross profit reached $2.26 million; operating loss narrowed to $63.6 million from $470.4 million (prior period included $425 million IPR&D charge).
- Net loss was $59.0 million, or $0.17 per share, versus $462.5 million, or $1.89, a year ago. Six-month loss totals $112.2 million.
- Liquidity remains strong: cash and cash equivalents $247.9 million, marketable securities $359.8 million—about $607.7 million available, which management believes funds operations for ≥12 months.
- Balance-sheet leverage increased: $150 million revenue-interest financing and $47 million term loan lifted total liabilities to $274.3 million (up from $76.8 million at 12/31/24).
- R&D expense $27.4 million; SG&A $38.5 million support commercialization and pipeline. Shares outstanding: 342.3 million (7/31/25).
While the launch of IBTROZI establishes an initial revenue base, sustained losses, higher debt and continued heavy R&D spend underscore the need for successful market penetration and additional approvals to reach profitability.